<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378845</url>
  </required_header>
  <id_info>
    <org_study_id>2011-002127-17</org_study_id>
    <nct_id>NCT01378845</nct_id>
  </id_info>
  <brief_title>Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands</brief_title>
  <acronym>Anti-Vasospasm</acronym>
  <official_title>Monocenter, IIT, Open Controlled and Prospectiv Study to Define the Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers at Fingertips Throughout the Medicinal Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christoph Hehrlein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the prognostic influence of light rheography
      measurement at the fingertips from subjects with secundary Raynaud syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Digital Ulcers (DU) belong to one of the most prevalent complications of systemic scleroses,
      leading in course to considerable impairment in everyday and professional life. The aetiology
      of the emergence of DU in patients with systemic scleroses (SSc) is complex, whereas the
      disease itself is primarily characterized by a vasculopathy of the small arterial vessels. In
      the course of the disease this chronic infection leads to fibrotic intimal hyperplasia,
      adventitial fibrosis, and thus to a significant lumen narrowing. So far, a number of
      independent risk factors have been identified, such as male gender, chronic infections of the
      esophagus, pulmonary-arterial hypertension, evidence of specific antibodies (e.g. anti-Scl70)
      in the blood, or the a previous manifestation of a Raynoud Syndrom.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of the blood flow before, during and after the medical therapy</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary objective of this study is defined by the dynamics of the (post)capillary blood flow before (baseline value) and 12 weeks after treatment, measured by means of the LRR. In doing so, the therapeutic effect, in terms of the change in (post)capillary blood flow after treatment compared to baseline value, is to be quantitatively determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emerge of new ulcers</measure>
    <time_frame>&gt; 24 weeks</time_frame>
    <description>Additionally, it is to be examined if new DUs emerge after 24 weeks or not. The prospects for recovery of the DU will be investigated by means of visual analogue scale (VAS), photo-documentation, and D-LRR after 2, 6, 12, and 24 weeks of medicinal therapy. Furthermore, as mentioned above, the change in the HIF-1alpha gene expression before (baseline value) and 6 weeks after treatment is to be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Raynaud's Phenomenon</condition>
  <condition>Skin Necrosis</condition>
  <arm_group>
    <arm_group_label>Prostavasin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostavasin + Bosentan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tracleer</intervention_name>
    <description>14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o</description>
    <arm_group_label>Prostavasin + Bosentan</arm_group_label>
    <other_name>Bosentan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostavasin</intervention_name>
    <description>Prostavasin 60 µg i.v, 5 days per week for 2 weeks</description>
    <arm_group_label>Prostavasin</arm_group_label>
    <arm_group_label>Prostavasin + Bosentan</arm_group_label>
    <other_name>Aprostadil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Limited or diffuse systemic sclerosis/scleroderma with at least one
             ulcera at fingertip

          -  Age &gt; 18 Years

          -  Weight &gt; 40 Kg

        Exclusion Criteria:

          -  Sympathectomy

          -  Ulcers due to other condition (PVD, DM, Thromboangiitis obliterans etc.)

          -  Antibiotic concomitant medication

          -  Therapy with Prostanoids within the last 4 weeks

          -  Previous Bosentan therapy

          -  Severe liver and renal insufficiency(creatinin &gt;2.0 mg/dl;AST/ALT &gt; 3X UNL)

          -  severe cardiac- pulmonal diseases

          -  Untreated or therapy refractory Hypertension

          -  Noncompliance

          -  Pregnancy or nursing (Pregnancy test required)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Kerber, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik Freiburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Hehrlein, Prof. Dr. med.</last_name>
    <phone>+49 761 270 77090</phone>
    <email>christoph.hehrlein@uniklinik-freiburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Kerber, Dr. med.</last_name>
    <phone>+49 761 270 36920</phone>
    <email>mark.kerber@uniklinik-freiburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kerber, MD</last_name>
      <email>mark.kerber@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>christoph Hehrlein, MD</last_name>
      <email>christoph.hehrlein@uniklinik-freiburg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>-Distler O, Gay S. [Scleroderma]. Internist (Berl) 2010; 51(1):30-38. -Mouthon L, Mestre-Stanislas C, Berezne A et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010; 69(1):214-217. -Denton C, Krieg T, Guillevin L. The burden of complications in patients with digital ulcers (DU) and systemic sclerosis (SSc): Preliminary findings from the DUO-Registry. 2009: 273. -Korn JH, Mayes M, Matucci CM et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50(12):3985-3993. -Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357(9273):2042-2048.</citation>
  </reference>
  <reference>
    <citation>-Sunderkotter C, Herrgott I, Bruckner C et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009; 160(4):835-843. -Muller-Ladner U. Akrale Ischämiesyndrome: vom Raynaud-Syndrom zur systemischen Sklerose. Bremen/London/Boston: UNI-MED Verlag AG, 2009 -Arab A, Kuemmerer K, Wang J et al. Oxygenated perfluorochemicals improve cell survival during reoxygenation by pacifying mitochondrial activity. J Pharmacol Exp Ther 2008; 325(2):417-424. -Pope J, Fenlon D, Thompson A et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000;(2):CD000953. -Kawald A, Burmester GR, Huscher D et al. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol 2008; 35(9):1830-1837. -Kowal-Bielecka O, Landewe R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68(5):620-628. -Sunderkotter C, Riemekasten G. [Raynaud phenomenon in dermatology:Part 2:therapy]. Hautarzt 2006; 57(10):927-938. -Ludwig M. Angiologie in Klinik und Praxis. 1 ed. Stuttgart: Thieme Verlag, 1998; 1-334.</citation>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Christoph Hehrlein</investigator_full_name>
    <investigator_title>Professor Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Morbus Raynaud</keyword>
  <keyword>Ulcera Hands, Toes</keyword>
  <keyword>Vasospastic disorder</keyword>
  <keyword>Raynaud's phenomenon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

